Full Text View
Tabular View
No Study Results Posted
Related Studies
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
This study has been completed.
Study NCT00661427   Information provided by Memorial Sloan-Kettering Cancer Center

First Received on January 7, 2008.   Last Updated on August 17, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Head and Neck
Squamous Cell Cancer
Additional conditions recognized in this trial
Carcinoma, Squamous Cell
Neoplasms, Squamous Cell
More general conditions related to this trial
Carcinoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
cetuximab
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
ImClone LLC
National Comprehensive Cancer Network


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services